Short-Term ONX-0914 Administration: Performance and Muscle Phenotype in Mdx Mice
Abstract
:1. Introduction
2. Materials and Methods
2.1. Animals
2.2. Experimental Design
2.3. Walking Speed
2.4. Strength
2.5. Muscle Tissue Harvest
2.6. Histology
2.7. Proteasome Preparation
2.8. Immunoblotting
2.9. Statistical Analysis
3. Results
3.1. Phenotype Characteristics of WT and MDX Mice at Seven Weeks of Age
3.2. ONX-0914 Treatment In Vivo: WT Mice
3.3. ONX-0914 Treatment In Vivo: MDX Mice
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Guiraud, S.; Davies, K.E. Regenerative biomarkers for Duchenne muscular dystrophy. Neural Regen. Res. 2019, 14, 1317–1320. [Google Scholar] [CrossRef] [PubMed]
- Rybakova, I.N.; Patel, J.R.; Ervasti, J.M. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J. Cell Biol. 2000, 150, 1209–1214. [Google Scholar] [CrossRef]
- Davies, K.E.; Nowak, K.J. Molecular mechanisms of muscular dystrophies: Old and new players. Nat. Rev. Mol. Cell Biol. 2006, 7, 762–773. [Google Scholar] [CrossRef] [PubMed]
- Kharraz, Y.; Guerra, J.; Pessina, P.; Serrano, A.L.; Munoz-Canoves, P. Understanding the process of fibrosis in Duchenne muscular dystrophy. BioMed Res. Int. 2014, 2014, 965631. [Google Scholar] [CrossRef] [PubMed]
- Chen, C.N.; Graber, T.G.; Bratten, W.M.; Ferrington, D.A.; Thompson, L.V. Immunoproteasome in animal models of Duchenne muscular dystrophy. J. Muscle Res. Cell Motil. 2014, 35, 191–201. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gawlik, K.I. At the crossroads of clinical and preclinical research for muscular dystrophy-are we closer to effective treatment for patients? Int. J. Mol. Sci. 2018, 19, 1490. [Google Scholar] [CrossRef] [Green Version]
- Grounds, M.D.; Radley, H.G.; Lynch, G.S.; Nagaraju, K.; De Luca, A. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol. Dis. 2008, 31, 1–19. [Google Scholar] [CrossRef] [Green Version]
- Giordano, C.; Mojumdar, K.; Liang, F.; Lemaire, C.; Li, T.; Richardson, J.; Divangahi, M.; Qureshi, S.; Petrof, B.J. Toll-like receptor 4 ablation in mdx mice reveals innate immunity as a therapeutic target in Duchenne muscular dystrophy. Hum. Mol. Genet. 2015, 24, 2147–2162. [Google Scholar] [CrossRef] [Green Version]
- Porter, J.D.; Khanna, S.; Kaminski, H.J.; Rao, J.S.; Merriam, A.P.; Richmonds, C.R.; Leahy, P.; Li, J.; Guo, W.; Andrade, F.H. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum. Mol. Genet. 2002, 11, 263–272. [Google Scholar] [CrossRef] [Green Version]
- Sinadinos, A.; Young, C.N.; Al-Khalidi, R.; Teti, A.; Kalinski, P.; Mohamad, S.; Floriot, L.; Henry, T.; Tozzi, G.; Jiang, T.; et al. P2RX7 purinoceptor: A therapeutic target for ameliorating the symptoms of Duchenne muscular dystrophy. PLoS Med. 2015, 12, e1001888. [Google Scholar] [CrossRef]
- Villalta, S.A.; Rosenthal, W.; Martinez, L.; Kaur, A.; Sparwasser, T.; Tidball, J.G.; Margeta, M.; Spencer, M.J.; Bluestone, J.A. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci. Transl. Med. 2014, 6, 258ra142. [Google Scholar] [CrossRef]
- Gazzerro, E.; Baldassari, S.; Assereto, S.; Fruscione, F.; Pistorio, A.; Panicucci, C.; Volpi, S.; Perruzza, L.; Fiorillo, C.; Minetti, C.; et al. Enhancement of muscle T regulatory cells and improvement of muscular dystrophic process in mdx mice by blockade of extracellular ATP/P2X axis. Am. J. Pathol. 2015, 185, 3349–3360. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Boer, J.M.; de Meijer, E.J.; Mank, E.M.; van Ommen, G.B.; den Dunnen, J.T. Expression profiling in stably regenerating skeletal muscle of dystrophin-deficient mdx mice. Neuromuscul. Disord. 2002, 12, S118–S124. [Google Scholar] [CrossRef]
- Porter, J.D.; Merriam, A.P.; Leahy, P.; Gong, B.; Feuerman, J.; Cheng, G.; Khanna, S. Temporal gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm identifies conserved and muscle group-specific mechanisms in the pathogenesis of muscular dystrophy. Hum. Mol. Genet. 2004, 13, 257–269. [Google Scholar] [CrossRef] [PubMed]
- Baban, D.; Davies, K.E. Microarray analysis of mdx mice expressing high levels of utrophin: Therapeutic implications for dystrophin deficiency. Neuromuscul. Disord. 2008, 18, 239–247. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.H.; Lawler, J.M. Amplification of proinflammatory phenotype, damage, and weakness by oxidative stress in the diaphragm muscle of mdx mice. Free Radic. Biol. Med. 2012, 52, 1597–1606. [Google Scholar] [CrossRef] [PubMed]
- Bushby, K.; Finkel, R.; Birnkrant, D.J.; Case, L.E.; Clemens, P.R.; Cripe, L.; Kaul, A.; Kinnett, K.; McDonald, C.; Pandya, S.; et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: Implementation of multidisciplinary care. Lancet Neurol. 2010, 9, 177–189. [Google Scholar] [CrossRef]
- Guiraud, S.; Edwards, B.; Babbs, A.; Squire, S.E.; Berg, A.; Moir, L.; Wood, M.J.; Davies, K.E. The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy. Hum. Mol. Genet. 2019, 28, 2189–2200. [Google Scholar] [CrossRef] [Green Version]
- Guiraud, S.; Davies, K.E. Pharmacological advances for treatment in Duchenne muscular dystrophy. Curr. Opin. Pharmacol. 2017, 34, 36–48. [Google Scholar] [CrossRef]
- Guiraud, S.; Aartsma-Rus, A.; Vieira, N.M.; Davies, K.E.; van Ommen, G.J.; Kunkel, L.M. The pathogenesis and therapy of muscular dystrophies. Annu. Rev. Genom. Hum. Genet. 2015, 16, 281–308. [Google Scholar] [CrossRef] [Green Version]
- Ferrington, D.A.; Gregerson, D.S. Immunoproteasomes: Structure, function, and antigen presentation. Prog. Mol. Biol. Transl. Sci. 2012, 109, 75–112. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ferrington, D.A.; Husom, A.D.; Thompson, L.V. Altered proteasome structure, function, and oxidation in aged muscle. FASEB J. 2005, 19, 1–24. [Google Scholar] [CrossRef]
- Husom, A.D.; Peters, E.A.; Kolling, E.A.; Fugere, N.A.; Thompson, L.V.; Ferrington, D.A. Altered proteasome function and subunit composition in aged muscle. Arch. Biochem. Biophys. 2004, 421, 67–76. [Google Scholar] [CrossRef] [PubMed]
- Liu, H.; Thompson, L.V. Skeletal muscle denervation investigations: Selecting an experimental control wisely. Am. J. Physiol. Cell Physiol. 2019, 316, C456–C461. [Google Scholar] [CrossRef] [PubMed]
- Liu, H.M.; Ferrington, D.A.; Baumann, C.W.; Thompson, L.V. Denervation-induced activation of the standard proteasome and immunoproteasome. PLoS ONE 2016, 11, e0166831. [Google Scholar] [CrossRef] [PubMed]
- Baumann, C.W.; Kwak, D.; Ferrington, D.A.; Thompson, L.V. Downhill exercise alters immunoproteasome content in mouse skeletal muscle. Cell Stress Chaperones 2018, 23, 507–517. [Google Scholar] [CrossRef] [PubMed]
- Farini, A.; Sitzia, C.; Cassani, B.; Cassinelli, L.; Rigoni, R.; Colleoni, F.; Fusco, N.; Gatti, S.; Bella, P.; Villa, C.; et al. Therapeutic potential of immunoproteasome inhibition in Duchenne muscular dystrophy. Mol. Ther. 2016, 24, 1898–1912. [Google Scholar] [CrossRef] [Green Version]
- Muchamuel, T.; Basler, M.; Aujay, M.A.; Suzuki, E.; Kalim, K.W.; Lauer, C.; Sylvain, C.; Ring, E.R.; Shields, J.; Jiang, J.; et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat. Med. 2009, 15, 781–787. [Google Scholar] [CrossRef] [Green Version]
- Kalim, K.W.; Basler, M.; Kirk, C.J.; Groettrup, M. Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J. Immunol. 2012, 189, 4182–4193. [Google Scholar] [CrossRef]
- Mundt, S.; Basler, M.; Buerger, S.; Engler, H.; Groettrup, M. Inhibiting the immunoproteasome exacerbates the pathogenesis of systemic Candida albicans infection in mice. Sci. Rep. 2016, 6, 19434. [Google Scholar] [CrossRef]
- Althof, N.; Goetzke, C.C.; Kespohl, M.; Voss, K.; Heuser, A.; Pinkert, S.; Kaya, Z.; Klingel, K.; Beling, A. The immunoproteasome-specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis. EMBO Mol. Med. 2018, 10, 200–218. [Google Scholar] [CrossRef] [PubMed]
- Basler, M.; Dajee, M.; Moll, C.; Groettrup, M.; Kirk, C.J. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J. Immunol. 2010, 185, 634–641. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kimura, H.; Usui, F.; Karasawa, T.; Kawashima, A.; Shirasuna, K.; Inoue, Y.; Komada, T.; Kobayashi, M.; Mizushina, Y.; Kasahara, T.; et al. Immunoproteasome subunit LMP7 deficiency improves obesity and metabolic disorders. Sci. Rep. 2015, 5, 15883. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Spencer, M.J.; Walsh, C.M.; Dorshkind, K.A.; Rodriguez, E.M.; Tidball, J.G. Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity. J. Clin. Investig. 1997, 99, 2745–2751. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, Y.; Beyer, A.; Aebersold, R. On the dependency of cellular protein levels on mRNA abundance. Cell 2016, 165, 535–550. [Google Scholar] [CrossRef] [Green Version]
- Koerner, J.; Brunner, T.; Groettrup, M. Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice. Oncotarget 2017, 8, 50873–50888. [Google Scholar] [CrossRef] [Green Version]
- Basler, M.; Mundt, S.; Muchamuel, T.; Moll, C.; Jiang, J.; Groettrup, M.; Kirk, C.J. Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol. Med. 2014, 6, 226–238. [Google Scholar] [CrossRef]
- Ettari, R.; Zappala, M.; Grasso, S.; Musolino, C.; Innao, V.; Allegra, A. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. Pharmacol. Ther. 2018, 182, 176–192. [Google Scholar] [CrossRef]
- Baumann, C.W.; Kwak, D.; Thompson, L.V. Assessing onset, prevalence and survival in mice using a frailty phenotype. Aging (Albany Ny) 2018, 10, 4042–4053. [Google Scholar] [CrossRef]
- Kwak, D.; Baumann, C.W.; Thompson, L.V. Identifying characteristics of frailty in female mice using a phenotype assessment tool. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 2020, 75, 640–646. [Google Scholar] [CrossRef]
- Hyzewicz, J.; Tanihata, J.; Kuraoka, M.; Nitahara-Kasahara, Y.; Beylier, T.; Ruegg, U.T.; Vater, A.; Takeda, S. Low-intensity training and the C5a complement antagonist NOX-D21 rescue the mdx phenotype through modulation of inflammation. Am. J. Pathol. 2017, 187, 1147–1161. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huber, E.M.; Basler, M.; Schwab, R.; Heinemeyer, W.; Kirk, C.J.; Groettrup, M.; Groll, M. Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 2012, 148, 727–738. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ichikawa, H.T.; Conley, T.; Muchamuel, T.; Jiang, J.; Lee, S.; Owen, T.; Barnard, J.; Nevarez, S.; Goldman, B.I.; Kirk, C.J.; et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum. 2012, 64, 493–503. [Google Scholar] [CrossRef] [PubMed]
- Dimasuay, K.G.; Sanchez, A.; Schaefer, N.; Polanco, J.; Ferrington, D.A.; Chu, H.W. Immunoproteasomes as a novel antiviral mechanism in rhinovirus-infected airways. Clin. Sci (Lond) 2018, 132, 1711–1723. [Google Scholar] [CrossRef]
- Liong, S.; Lappas, M. Markers of protein synthesis are increased in fetal membranes and myometrium after human labour and delivery. Reprod. Fertil. Dev. 2018, 30, 313–329. [Google Scholar] [CrossRef] [Green Version]
- Groettrup, M.; Kirk, C.J.; Basler, M. Proteasomes in immune cells: More than peptide producers? Nat. Rev. Immunol. 2010, 10, 73–78. [Google Scholar] [CrossRef] [Green Version]
- Chang, L.; Niu, F.; Chen, J.; Cao, X.; Liu, Z.; Bao, X.; Xu, Y. Ghrelin improves muscle function in dystrophin-deficient mdx mice by inhibiting NLRP3 inflammasome activation. Life Sci. 2019, 232, 116654. [Google Scholar] [CrossRef]
- Capogrosso, R.F.; Mantuano, P.; Cozzoli, A.; Sanarica, F.; Massari, A.M.; Conte, E.; Fonzino, A.; Giustino, A.; Rolland, J.F.; Quaranta, A.; et al. Contractile efficiency of dystrophic mdx mouse muscle: In vivo and ex vivo assessment of adaptation to exercise of functional end points. J. Appl. Physiol. 2017, 122, 828–843. [Google Scholar] [CrossRef]
- McGeachie, J.K.; Grounds, M.D.; Partridge, T.A.; Morgan, J.E. Age-related changes in replication of myogenic cells in mdx mice: Quantitative autoradiographic studies. J. Neurol. Sci. 1993, 119, 169–179. [Google Scholar] [CrossRef]
- DiMario, J.X.; Uzman, A.; Strohman, R.C. Fiber regeneration is not persistent in dystrophic (MDX) mouse skeletal muscle. Dev. Biol. 1991, 148, 314–321. [Google Scholar] [CrossRef]
Target Proteins | Protein Load (µg) | Primary Antibody | Secondary Antibody | ||
---|---|---|---|---|---|
Host | Dilution | Host | Dilution | ||
α7 | 20 | M | 1:1000 | M | 1:15,000 |
LMP2 | 40 | M | 1:500 | M | 1:15,000 |
LMP7 | 20 | M | 1:500 | M | 1:15,000 |
Parameters | WT-Vehicle (7 Weeks) | WT-ONX (7 Weeks) |
---|---|---|
Body weight (g) | 24 ± 0.6 | 22 ± 0.8 |
TA weight (mg) | 42 ± 1.2 | 38 ± 0.7 |
EDL weight (mg) | 8.8 ± 0.4 | 9.1 ± 1.5 |
Strength (g) | 228 ± 5 | 221 ± 6 |
Walking speed (sec) | 102 ± 11 | 126 ± 22 |
EDL muscle | ||
CSA (µm2) | 1185 ± 104 | 1077 ± 32 |
Central nuclei (%) | 2.0 ± 0.3 | 1.4 ± 0.2 |
CD45+ cells (number/field) | 3.8 ± 0.8 | 3.3 ± 0.3 |
Ratio of TA weight to body weight (mg/g) | 1.7 ± 0.04 | 1.7 ± 0.04 |
Ratio of EDL weight to body weight (mg/g) | 0.4 ± 0.02 | 0.4 ± 0.06 |
Ratio of strength to body weight (g/g) | 9.5 ± 0.4 | 10.0 ± 0.4 |
Ratio of walking speed to body weight (sec/g) | 4.3 ± 0.6 | 5.7 ± 1.0 |
Parameters | MDX-Vehicle (7 Weeks) | MDX-ONX (7 Weeks) |
---|---|---|
Body weight (g) | 25 ± 0.3 | 24 ± 0.4 |
TA weight (mg) | 54 ± 2.0 | 51 ± 1.2 |
EDL weight (mg) | 11.1 ± 0.5 | 11.0 ± 0.5 |
Strength (g) | 190 ± 8 | 197 ± 4 |
Walking speed (s) | 70 ± 5 | 73 ± 7 |
EDL muscle | ||
CSA (µm2) | 1237 ± 54 | 1111 ± 31 |
Central nuclei (%) | 59 ± 1.4 | 58 ± 1.9 |
CD45+ cells (number/field) | 17 ± 0.8 | 17 ± 1.1 |
Ratio of TA weight to body weight (mg/g) | 2.2 ± 0.07 | 2.1 ± 0.04 |
Ratio of EDL weight to body weight (mg/g) | 0.4 ± 0.02 | 0.5 ± 0.02 |
Ratio of strength to body weight (g/g) | 7.7 ± 0.3 | 8.2 ± 0.2 |
Ratio of walking speed to body weight (s/g) | 2.8 ± 0.2 | 3.0 ± 0.3 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kwak, D.; Wei, G.; Thompson, L.V.; Kim, J.-H. Short-Term ONX-0914 Administration: Performance and Muscle Phenotype in Mdx Mice. Int. J. Environ. Res. Public Health 2020, 17, 5211. https://doi.org/10.3390/ijerph17145211
Kwak D, Wei G, Thompson LV, Kim J-H. Short-Term ONX-0914 Administration: Performance and Muscle Phenotype in Mdx Mice. International Journal of Environmental Research and Public Health. 2020; 17(14):5211. https://doi.org/10.3390/ijerph17145211
Chicago/Turabian StyleKwak, Dongmin, Guoxian Wei, LaDora V. Thompson, and Jong-Hee Kim. 2020. "Short-Term ONX-0914 Administration: Performance and Muscle Phenotype in Mdx Mice" International Journal of Environmental Research and Public Health 17, no. 14: 5211. https://doi.org/10.3390/ijerph17145211